Skip to main content

Table 1 Clinical and pathological characteristics

From: MEK targeting in N-RAS mutated metastatic melanoma

Clinical characteristics B-RAF mutated N-RAS mutated Wild type P value
N = 144 N = 63 (43.7) N = 40 (27.7) N = 41 (28.4)  
Frequency of mutations V600E 47(74.6) Q61R 16 (40)   
   V600K 12 (19) Q61K 12 (30)   
   V600R/L 2 (3.1) Q61L 6 (15)   
   Unknown 2 (3.1) Q61H 4 (10)   
     G12D/V 2 (5)   
Sex Male 42 (66) 25 (62) 22 (54) 0.21
  Female 21 (33) 15 (38) 19 (46)  
Median age (years) 57.6 68.2 66.3 <0.0001
LDH Elevated 28 19 20 0.6
Normal 24 6 12  
Unknown 11 15 9  
M stage M1a 13 8 9 0.3
M1b 11 14 9  
M1c 39 18 23
Soft tissue and skin metastasis 23 (37) 28 (70) 17 (41) 0.0025
Lymph node metastasis 29 (46) 30 (75) 25 (61) 0.01
Lung metastasis 41 (65) 24 (60) 27 (66) 0.8
Liver metastasis 25 (39) 11 (27) 17 (41) 0.3
Bone metastasis 17 7 6 0.3
CNS metastasis 31 (49) 16 (40) 16 (39) 0.5
Median survival from diagnosis of stage IV disease 18.3 13.0 19.6 0.17